Absorption of interferon alpha from patches in rats

Journal of Drug Targeting

Volumn 13, Issue 6, 2005, Pages 383-390

  Ito, Yukako ^a   Tosh, Biranchinarayan ^a   Togashi, Yusuke ^a   Amagase, Kikuko ^a   Kishida, Tsunao ^b   Kishida, Tsunataro ^b   Sugioka, Nobuyuki ^a   Shibata, Nobuhito ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b Louis Pasteur Center for Medical Research   (Japan)

Author keywords

Absorption enhancer; Bioavailability; Gelucire44 14; HCO 60; Interferon ; Labrasol; Oral patch; Rats

Indexed keywords

ALPHA INTERFERON; GELUCIRE; LABRASOL; POLYMER; RICINOMACROGOL; SURFACTANT; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG RELEASE; DUODENUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; ILEUM; IN VITRO STUDY; INTESTINE ABSORPTION; JEJUNUM; MALE; MEAN RESIDENCE TIME; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SMALL INTESTINE MUCOSA; SOLUBILITY; SURFACE PROPERTY;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CASTOR OIL; CHEMISTRY, PHARMACEUTICAL; INTERFERON-ALPHA; INTESTINAL ABSORPTION; JEJUNUM; MALE; ORGANIC CHEMICALS; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SURFACE-ACTIVE AGENTS;

EID: 28044469085     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860500331506     Document Type: Article

References (27)

1. Anderbarg EK, Lindmark T, Artursson P. 1993. Sodium caprate elicits dilations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm Res 10:857-864.
2. Ansel HC, Allen Jr, LV, Popovich NG. 1999. Pharmaceutical dosage forms and drug delivery systems. Baltimore: Lippincott Williams & Wilkins. p 106.
3. Eaimtrakarn S, Itoh Y, Kishimoto J, Yoshikawa Y, Shibata N, Takada K. 2001. Retention and transit of intestinal mucoadhesive films in rat small intestine. Int J Pharm 224:61-67.
4. Eaimtrakarn S, Itoh Y, Kishimoto J, Yoshikawa Y, Shibata N, Murakami M, Takada K. 2002a. Gastrointestinal mucoadhesive patch system (GI-MAPS) for oral administration of G-CSF, a model protein. Biomaterials 23:145-152.
5. Eaimtrakarn S, Rama Prasad YV, Puthli SP, Yoshikawa Y, Shibata N, Takada K. 2002b. Evaluation of gastrointestinal transit characteristics of oral patch preparation using caffeine as a model drug in human volunteers. Drug Metab Pharmacokinet 17:284-291.
6. Eiamtrakarn S, Rama Prasad YV, Puthli SP, Yoshikawa Y, Shibata N, Takada K. 2003. Possibility of a patch system as a new oral delivery system. Int J Pharm 250:111-117.
7. Eyles JE, Alpar HO, Conway BR, Keswick M. 1997. Oral delivery and fate of poly (lactic acid) microsphere-encapsulated interferon in rats. J Pharm Pharmacol 49:669-674.
8. Hoofnagle JH. 1998. Therapy of viral hepatitis. Digestion 59:563-578.
9. Jani PU, McCarthy DE, Florence AT. 1994. Titanium dioxide (rutile) particle uptake from the rat GI tract and translocation to systemic organs after oral administration. Int J Pharm 105:157-168.
10. Jenkins PG, Howard KA, Blackhall NW, Thomas NW, Davis SS, O'Hagan DT. 1994. The quantitation of the absorption of microparticles into the intestinal lymph of Wistar rats. Int J Pharm 102:261-266.
11. Koga K, Kawashima S, Murakmi M. 2002. In vitro and in situ evidence for the contribution of Labrasol and Gelcire44/14 on transport of cephalexin and cefoperazone by rat intestine. Eur J Pharm Biopharm. 54:311-318.
12. Lee YH, Perry BA, Sutyak JP, Stem W, Sinko PJ. 2000. Regional differences in intestinal spreading and pH recovery and the impact on salmon calcitonin in dogs. Pharm Res 17:284-290.
13. Marcus PI, Van der Heide L, Sekellick MJ. 1999. Special topics issue: Oral use of interferons and cytoldnes. J Interferon Cytokin Res 19:813-879.
14. McHutchison J, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling AM, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng J Med 339:1485-1492.
15. Mori S, Matsuura A, Rama Prasad YV, Takada K. 2004. Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats. Biol Pharm. Bull 27:418-421.
16. Patel K, McHutcison J. 2001. Peginterferon alpha-2b: A new approach to improving response in hepatitis C patients. Expert Opin Pharmacother 2:307-1315.
17. Poynard T, Marcellin P, Lee SS, Niderau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomizedtrial of interferon alfa-2b plus ribavirin for 48 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C infection. Lancet 352:1426-1432.
18. Rama Prasad YV, Minamitnoto T, Yoshikawa Y, Shibata N, Mori S, Matsuura A, Takada K. 2004. In situ intestinal absorption studies on low molecular weight heparin in rats using Labrasol as absorption enhancer. Int J Pharm 271:225-232.
19. Russell-Jones J. 1999. Carrier-mediated transport; oral drug delivery. In: Mathiowitz E, editor. Encyclopedia of controlled drug delivery. New York: John Wiley & Sons. p 173-184.
20. Sato A, Sone S. 2003. A peptide mimetic of human interferon (IFN)-β. Biochem J 371:603-608.
21. Sinko PJ, Lee YH, Makhey V, Leesman GD, Sutyak JP, Yu H, Perry B, Smith CL, Hu P, Wagner EJ, et al. 1999. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: In vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm Res 16:527-533.
22. Soos JM, Mujitaba MG, Subramanian PS, Streit WJ, Johnson HM. 1997. Oral feeding of interferon τ can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J Neroimmunol 75:43-50.
23. Takayama S, Iwaki K, Nishida Y, Tanaka M, Fujii M, Ohashi K, Ikeda M, Kuramoto M. 1990. Effect of oral administration of interferon-α on antibody production in mice with induced tolerance. J Interferon Cytokin Res 19:895-900.
24. Trying SK. 1995. Interferons: Biochemistry and mechanism of action. Am J Obstet Gynecol 172:1350-1353.
25. Venkatesan N, Uchino K, Amagase K, Ito Y, Shibata N, Tkada K. n.d. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics. Biomaterials, in press.
26. Whitehead K, Shen Z, Mitragotri S. 2004. Oral delivery of macromolecules using intestinal patches: Applications for insulin delivery. J Control Rel 98:37-45.
27. Yoshikawa Y, Kato K, Sone H, Takada K. 1998. Development and evaluation of noncompartmental pharmacokinetic analysis program "WinHARMONY" using Visual BASIC language having a function of an automatic recognition of terminal elimination phase of plasma drug concentration vs time profile. Jpn J Clin Pharmacol Ther 29:475-487.